Taysha Gene Therapies announces positive TSHA-102 clinical data; IDMC approves early advancement to high dose cohort

Taysha Gene Therapies, Inc.

Longer-term adult data (up to 52 weeks) show durable improvements in motor, communication, autonomic, and seizure domains.
Adult patient 1 gained ability to sit unassisted for first time in over a decade; patient 2 seizure-free for 8.5 months at 25% lower anti-seizure medication.
Initial pediatric data (up to 22 weeks) show early developmental gains: improved hand function, gait, and communication via eye-gaze device.
IDMC approved early advancement to high dose cohort in pediatric trial; dosing expected Q3 2024 after review of adult high dose safety.
TSHA-102 generally well-tolerated with no drug-related serious adverse events or dose-limiting toxicities in either trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.